Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

MEGESTROL ACETATE CRS (120 MG)

MEGESTROL ACETATE CRS (120 MG)

595-33-5

DISCOVER
RIVASTIGMINE IMPURITY D CRS (10 MG)

RIVASTIGMINE IMPURITY D CRS (10 MG)

415973-05-6

DISCOVER
RIVASTIGMINE HYDROGEN TARTRATE CRS (350 MG)

RIVASTIGMINE HYDROGEN TARTRATE CRS (350 MG)

129101-54-8

DISCOVER
HALOPERIDOL FOR SYSTEM SUITABILITY CRS (25 MG)

HALOPERIDOL FOR SYSTEM SUITABILITY CRS (25 MG)

52-86-8

DISCOVER
HALOPERIDOL FOR PEAK IDENTIFICATION CRS (20 MG)

HALOPERIDOL FOR PEAK IDENTIFICATION CRS (20 MG)

52-86-8

DISCOVER
PIOGLITAZONE FOR SYSTEM SUITABILITY CRS (15 MG)

PIOGLITAZONE FOR SYSTEM SUITABILITY CRS (15 MG)

112529-15-4

DISCOVER
PIOGLITAZONE HYDROCHLORIDE CRS (120 MG)

PIOGLITAZONE HYDROCHLORIDE CRS (120 MG)

112529-15-4

DISCOVER
AMOXICILLIN TRIHYDRATE  FOR PERFORMANCE VERIFICATION CRS (50

AMOXICILLIN TRIHYDRATE FOR PERFORMANCE VERIFICATION CRS (50

61336-70-7

DISCOVER
ANASTROZOLE CRS (100 MG)

ANASTROZOLE CRS (100 MG)

120511-73-1

DISCOVER
URSOLIC ACID CRS (25 MG)

URSOLIC ACID CRS (25 MG)

77-52-1

DISCOVER
MEGESTROL ACETATE FOR SYSTEM SUITABILITY CRS (50 MG)

MEGESTROL ACETATE FOR SYSTEM SUITABILITY CRS (50 MG)

595-33-5

DISCOVER
BASIC BUTYLATED METHACRYLATE COPOLYMER CRS (20 MG)

BASIC BUTYLATED METHACRYLATE COPOLYMER CRS (20 MG)

24938-16-7

DISCOVER